Your Messages Inbox
Your Article Summary
See Latest ArticlesGSK and Xenoport resubmit new drug application for Solzira in restless legs syndrome
XenoPort, 01/20/09
GlaxoSmithKline and XenoPort, Inc. announced that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor